PURPOSE: Our aim was to evaluate in anaplastic thyroid carcinoma (ATC) patients the value of 18F-FDG PET/CT compared with total body computed tomography (CT) using intravenous contrast material for initial staging, prognostic assessment, therapeutic monitoring and follow-up. METHODS: Twenty consecutive ATC patients underwent PET/CT for initial staging. PET/CT was performed again during follow-up. The gold standard was progression on imaging follow-up (CT or PET/CT) or confirmation with another imaging modality. RESULTS: A total of 265 lesions in 63 organs were depicted in 18 patients. Thirty-five per cent of involved organs were demonstrated only with PET/CT and one involved organ only with CT. In three patients, the extent of disease was significantly changed with PET/CT that demonstrated unknown metastases. Initial treatment modalities were modified by PET/CT findings in 25% of cases. The volume of FDG uptake (≥300 ml) and the intensity of FDG uptake (SUVmax≥18) were significant prognostic factors for survival. PET/CT permitted an earlier assessment of tumour response to treatment than CT in 4 of the 11 patients in whom both examinations were performed. After treatment with combined radiotherapy and chemotherapy, only the two patients with a negative control PET/CT had a confirmed complete remission at 14 and 38 months; all eight patients who had persistent FDG uptake during treatment had a clinical recurrence and died. CONCLUSION: FDG PET/CT appears to be the reference imaging modality for ATC at initial staging and seems promising in the early evaluation of treatment response and follow-up.
PURPOSE: Our aim was to evaluate in anaplastic thyroid carcinoma (ATC) patients the value of 18F-FDG PET/CT compared with total body computed tomography (CT) using intravenous contrast material for initial staging, prognostic assessment, therapeutic monitoring and follow-up. METHODS: Twenty consecutive ATC patients underwent PET/CT for initial staging. PET/CT was performed again during follow-up. The gold standard was progression on imaging follow-up (CT or PET/CT) or confirmation with another imaging modality. RESULTS: A total of 265 lesions in 63 organs were depicted in 18 patients. Thirty-five per cent of involved organs were demonstrated only with PET/CT and one involved organ only with CT. In three patients, the extent of disease was significantly changed with PET/CT that demonstrated unknown metastases. Initial treatment modalities were modified by PET/CT findings in 25% of cases. The volume of FDG uptake (≥300 ml) and the intensity of FDG uptake (SUVmax≥18) were significant prognostic factors for survival. PET/CT permitted an earlier assessment of tumour response to treatment than CT in 4 of the 11 patients in whom both examinations were performed. After treatment with combined radiotherapy and chemotherapy, only the two patients with a negative control PET/CT had a confirmed complete remission at 14 and 38 months; all eight patients who had persistent FDG uptake during treatment had a clinical recurrence and died. CONCLUSION:FDG PET/CT appears to be the reference imaging modality for ATC at initial staging and seems promising in the early evaluation of treatment response and follow-up.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Tae Yong Kim; Kyung Won Kim; Tae Sik Jung; Jung Min Kim; Sun Wook Kim; Ki-Wook Chung; Eun Young Kim; Gyungyub Gong; Young Lyun Oh; Soo Youn Cho; Ka Hee Yi; Won Bae Kim; Do Joon Park; Jae Hoon Chung; Bo Youn Cho; Young Kee Shong Journal: Head Neck Date: 2007-08 Impact factor: 3.147
Authors: O Nilsson; J Lindeberg; J Zedenius; E Ekman; J Tennvall; H Blomgren; L Grimelius; G Lundell; G Wallin Journal: World J Surg Date: 1998-07 Impact factor: 3.352
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: Nikola Besic; Marko Hocevar; Janez Zgajnar; Ana Pogacnik; Snjezana Grazio-Frkovic; Marija Auersperg Journal: Langenbecks Arch Surg Date: 2004-12-15 Impact factor: 3.445
Authors: W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Peter M Sadow; Dora Dias-Santagata; Zongli Zheng; Derrick T Lin; Long Phi Le; Carmelo Nucera Journal: Endocr Relat Cancer Date: 2015-12 Impact factor: 5.678
Authors: Bernard Caillou; Monique Talbot; Urbain Weyemi; Catherine Pioche-Durieu; Abir Al Ghuzlan; Jean Michel Bidart; Salem Chouaib; Martin Schlumberger; Corinne Dupuy Journal: PLoS One Date: 2011-07-21 Impact factor: 3.240
Authors: Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark Journal: Thyroid Date: 2021-03 Impact factor: 6.568